News - Glivec

Filter

Current filters:

Glivec

Popular Filters

US-India Business Council has concerns over India's ruling on Novartis' Glivec

03-04-2013

This week's long awaited Supreme Court of India ruling, which denied a patent on Swiss drug major Novartis'…

Asia-PacificGenericsGlivecNovartisPatentsPharmaceutical

India's Supreme Court denies Novartis Glivec patent appeal

02-04-2013

In a landmark decision issued on Monday (April 1) by the Indian Supreme Court has denied Swiss drug major…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain

09-01-2013

The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

Novartis Indian patent hearings close, but no verdict yet

05-12-2012

After more than 12 weeks of hearings in India's Supreme Court, humanitarian aid agency Medecins Sans…

Asia-PacificGlivecLegalNovartisPatentsPharmaceutical

MSF update on Novartis versus India, Supreme Court case

18-11-2012

Humanitarian health organization Medecins Sans Frontieres (MSF) says it continues to follow progress…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

Sanofi moves on Lemtrada; Novartis Indian patent case

21-08-2012

French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Novartis Indian Supreme Court hearings again re-scheduled

09-07-2012

Humanitarian aid agency Medecins Sans Frontieres said on Friday it has learnt that final arguments in…

Asia-PacificGenericsGleevecGlivecLegalNovartisPatentsPharmaceutical

"NICE" news for Novartis CML drugs, but not for Bristol-Myers

22-03-2012

In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

EMA panel backs Novartis Cushing’s disease drug; Glivec label change

23-01-2012

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EuropeGlivecNovartisOncologypasireotidePharmaceuticalRare diseasesRegulationSignifor

Mixed NICE recommendations for CML and diabetes drugs

13-01-2012

In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Novartis' imatinib patent battle resumes in Indian Supreme Court

15-08-2011

The controversial Novartis case in which the Swiss major Novartis (NOVN: VX) challenged the manner in…

Asia-PacificGleevecGlivecNovartisOncologyPatentsPharmaceutical

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor

06-05-2011

The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday…

AfinitorBristol-Myers SquibbGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Back to top